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Abstract
Background: Plasmodium falciparum re-emerged in Iquitos, Peru in 1994 and is now hypoendemic (< 0.5 infections/
person/year). Purportedly non-immune individuals with discrete (non-overlapping) P. falciparum infections can be 
followed using this population dynamic. Previous work demonstrated a strong association between this population's 
antibody response to PfMSP1-19KD and protection against febrile illness and parasitaemia. Therefore, some selection 
for PfMSP1-19KD allelic diversity would be expected if the protection is to allele-specific sites of PfMSP1-19KD. Here, the 
potential for allele-specific polymorphisms in this population is investigated, and the allele-specificity of antibody 
responses to PfMSP1-19KD are determined.
Methods: The 42KD region in PfMSP1 was genotyped from 160 individual infections collected between 2003 and 
2007. Additionally, the polymorphic block 2 region of Pfmsp1 (Pfmsp1-B2) was genotyped in 781 infection-months to 
provide a baseline for population-level diversity. To test whether PfMSP1-19KD genetic diversity had any impact on 
antibody responses, ELISAs testing IgG antibody response were performed on individuals using all four allele-types of 
PfMSP1-19KD. An antibody depletion ELISA was used to test the ability of antibodies to cross-react between allele-
types.
Results: Despite increased diversity in Pfmsp1-B2, limited diversity within Pfmsp1-42KD was observed. All 160 
infections genotyped were Mad20-like at the Pfmsp1-33KD locus. In the Pfmsp1-19KD locus, 159 (99.4%) were the Q-
KSNG-F haplotype and 1 (0.6%) was the E-KSNG-L haplotype. Antibody responses in 105 individuals showed that Q-
KNG and Q-TSR alleles generated the strongest immune responses, while Q-KNG and E-KNG responses were more 
concordant with each other than with those from Q-TSR and E-TSR, and vice versa. The immuno-depletion ELISAs 
showed all samples responded to the antigenic sites shared amongst all allelic forms of PfMSP1-19KD.
Conclusions: A non-allele specific antibody response in PfMSP1-19KD may explain why other allelic forms have not 
been maintained or evolved in this population. This has important implications for the use of PfMSP1-19KD as a 
vaccine candidate. It is possible that Peruvians have increased antibody responses to the shared sites of PfMSP1-19KD, 
either due to exposure/parasite characteristics or due to a human-genetic predisposition. Alternatively, these allelic 
polymorphisms are not immune-specific even in other geographic regions, implying these polymorphisms may be 
less important in immune evasion that previous studies suggest.
Background
If a population of parasites is able to evolve many different
allelic forms of its antigenic proteins while still maintaining
the biological function of each protein, it will increase the
ability of the parasite population as a whole to evade
immune responses. As a result, genetic diversity in anti-
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genic encoding genes can indicate evidence of protective
immune responses. However, diversity can also occur
through random mutation. If the mutations are not lethal,
they might be fixed in the population by random genetic
drift. Such a process is very likely in Plasmodium falci-
parum, where populations undergo frequent constrictions
(i.e. a genetic bottleneck, by drug selection pressure) and
subsequent clonal expansion/replacement that is not due to
selection. One powerful way to distinguish genes under
immune selection pressure from those that are varying as a
result of genetic drift is to combine genotyping data with
antibody data, to establish whether the antigen in question
generates an allele-specific immune response - that is, an
immune response that differentially targets and kills para-
sites having different allelic forms.
It is suggested that the most promising malaria vaccine
candidates are those which are developed against immuno-
genic regions of proteins that have been evolutionarily con-
served due to functionality constraints, and those in which
diversity is limited enough that is not likely to compromize
overall vaccine efficacy. A leading vaccine candidate is the
C-terminal 19KD portion of the Plasmodium falciparum
merozoite surface protein-1 (PfMSP1). PfMSP1 has a pri-
mary structure (195KD) [1] that can be divided into 17
blocks based on the conservation and variability of the
amino acid sequence [2-4]. PfMSP1-33KD (encoded by
block 16) is dimorphic, existing in two major allelic forms:
K1-like and Mad20-like. Both of these alleles are geneti-
cally conserved with few synonymous and non-synony-
mous amino acid substitutions within each allele class [2,4].
PfMSP1-19KD (encoded by block 17) is also relatively
conserved, with only a few single nucleotide polymor-
phisms (SNPs) identified in its two epidermal growth fac-
tor-like (EGF-like) domains. These PfMSP1-19KD EGF-
like domains appear to be functionally critical for erythro-
cyte invasion and elicit anti-parasite immune responses [4-
6]. The amino acid polymorphisms in PfMSP1-19KD
appear to have evolved in order to evade the human
immune response capable of blocking the parasite from
invading red blood cells [4,7-10] and are located in six
known locations: 1644 (E/Q), 1691 (K/T), 1699 (N/S),
1700 (N/S), 1701 (R/G) and 1716 (F/L) [4,11,12]. The
dimorphic nature of the amino acid polymorphism and the
resulting major forms of E-KNG, E-TSR, Q-KNG and Q-
TSR suggest that some of these alleles emerged by recom-
bination, although this might also be due to functional con-
straints inhibiting multiple changes of certain sites in one
evolutionary leap.
To determine if the four PfMSP1-19KD main allelic
forms result in naturally acquired allele-specific immunity,
studies have compared antibody responses among individu-
als naturally exposed to P. falciparum malaria. A study by
Shi et al [13] compared antibody responses against the four
major allele-types of PfMSP1-19KD in a population of
individuals highly exposed to all allelic forms [13]. Not sur-
prisingly, individuals could respond to various alleles.
However, it was noted that the anti-E-KNG and anti-Q-
KNG responses correlated more closely with each other,
and similarly the anti-E-TSR and anti-Q-TSR responses
correlated more closely, suggesting that the -KNG and -
TSR epitopes are targets of allele-specific immunity [13].
In a more recent study, Mamillapalli et al [14] developed an
assay to test allele-specific cross-reactivity/specificity [14].
By conducting an immuno-depletion assay on sera from
three acutely infected individuals (who had been previously
infected with many different allelic types), they observed
antibody responses to both allele-specific and shared sites
[14].
In order to advance vaccine candidate antigens such as
PfMSP1-19KD along the development pipeline, the range
of antigenic diversity in the targeted population must be
known, and also the likelihood that the antigen generates
antibody responses to shared sites that might be associated
with protection. The goal of the current study was to deter-
mine if there are different PfMSP1-19KD allelic forms cir-
culating at the study site in Iquitos, Peru, and whether P.
falciparum  infected individuals at the study site develop
antibody responses to shared (conserved) sites, or whether
the responses are allele-specific to the four main family
alleles: E-KNG, Q-KNG, E-TSR, and Q-TSR.
Since 2003, a longitudinal active case detection cohort
study, (Malaria Immunology and Genetics in the Amazon,
MIGIA) has been conducted in one of the highest malaria
transmission communities near Iquitos, Peru, called Zunga-
rococha, where P. falciparum malaria re-emerged in 1994
after more than 30 years of convalescence. Since the 1994-
1998 epidemic there has been sustained low transmission in
this region (< 0.5 P. falciparum infections/person/year in
Zungarococha since 2003) [15,16]. From infections occur-
ring between 2003 and 2007, Pfmsp1-42KD (Pfmsp1-
33KD + Pfmsp1-19KD) was PCR-genotyped to determine
family-type, and then Pfmsp1-19KD was sequenced to
determine the genetic diversity in this region. Additionally,
the population-level diversity was further characterized by
genotyping the polymorphic Pfmsp1-Block 2 (Pfmsp1-B2)
as a baseline for the potential population-level diversity.
PfMSP1-19KD antibody responses at the study site were
then measured to the four major PfMSP1-19KD allele-
types and antibody depletion ELISA experiments were per-
formed to determine the degree of cross-reactivity in the
antibody responses to each PfMSP1-19KD allele-type. The
results have implications for the development of PfMSP1
based vaccines.
Methods
Study design
Blood samples were collected in Zungarococha (N = 1907)
during the malaria transmission season (January-July) fromSutton et al. Malaria Journal 2010, 9:3
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2003 to 2007. Details on the study site and design are
described by Branch et al [16]. In brief, active case detec-
tion included a beginning and ending malaria season com-
munity-wide cross-sectional survey and also a selection of
approximately 200 individuals each month during the
malaria season for weekly visits for one month. Addition-
ally, there was passive case detection executed in the health
center. This study had ethical approval from U.S.A and
Peruvian ethical review boards, and all participants pro-
vided informed consent and/or assent, and these approvals
continue with annual review.
In the active case detection, blood slides from individuals
who had a body temperature of ≥38.3°C, reported having a
high fever within two days, or had a haematocrit < 30%
pcv, had their blood slides read by expert microscopists
within one day and were treated within one day if positive.
If an individual was asymptomatic, there could be six days
before reading the microscopy slide. At the next scheduled
visit (one week later) another blood sample was collected
and any individual who was found with malaria parasites on
the week before visit had their blood slide read immedi-
ately. Therefore, asymptomatic individuals have more than
one blood slide collected during a given infection before
treatment. Treatment regimens are reported in Branch et al
[16].
Sample selection for genotypification of Pfmsp1-33KD and 
Pfmsp1-19KD
Plasmodium falciparum infections were detected by
microscopy or by polymerase chain reaction (PCR) [16,17].
Sample size was estimated by comparing a known propor-
tion to an anticipated proportion, accounting for the detec-
tion of rare alleles occurring in this population at a rate of at
least one percent with a power of 80% [18]. To adequately
represent the population in this cohort, gender, age, com-
munity, and year of infection were considered when select-
ing samples.
PCR-genotyping of Pfmsp1-33KD and Pfmsp1-19KD
All samples selected for this study underwent a semi-
nested-PCR reaction. Due to the dimorphic nature of
Pfmsp1-42KD, family-specific primers for the Mad20 and
K1 allelic families were designed for both primary and sec-
ondary PCRs. To test whether recombinatory events were
occurring within these regions, all permutations of these
primers were tested on all samples. Primers were designed
from previously established sequences [4]. The primary
PCR amplifies an approximate 1200 bp region at the C-ter-
minal end of Pfmsp1, including both Pfmsp1-33KD and
Pfmsp1-19KD. Two primary PCRs were performed using
family-specific primers: Mad20 forward 5'-GCAATATCT-
GTCACAATGG (1358) or K1 forward 5'-GCAG-
TAACTCCTTCCGTAATTG (1329) in combination with a
universal reverse 5'-TTAGAGGAACTGCA-
GAAAATACCA (1729). Four secondary PCRs were per-
formed using amplified/non-amplified product form the
primary PCR, accounting for all possible permutations of
these primers. African clones positive for each individual
allele-type were used as positive controls. This PCR ampli-
fies  Pfmsp1-19KD and an N-terminal flanking region
(approximately 450 bp): Mad20 middle forward 5'-
CCATAACGACTTCGAAGC (1580) or K1 middle for-
ward 5'-CGTTGGAATTGCTGATTTATCAACAG (1585),
and the universal reverse (Figure 1, A and 1B).
Both primary and secondary PCRs were initially per-
formed in a 25 μL total reaction volume. If there was ampli-
fication in the secondary PCR, the secondary PCR was
performed again at an increased total reaction volume of
100 μL for sequencing. Mastermixes for primary and sec-
ondary PCRs were comprised of 5' and 3' primers [0.8 mM]
(Integrated DNA Technologies, Inc, Coralville, IA, USA),
deoxynucleoside triphosphate (dNTP) mixture [0.4 mM]
(Invitrogen™, Carlsbad, CA, USA), MgCl2 [1 mM] (Pro-
mega, Madison, WI, USA), 5× PCR buffer, 1 U of Taq
polymerase (Promega Go Taq Flexi, Madison, WI, USA),
molecular grade water, and blood extracted DNA (genomic
DNA adjusted to 20-40 ng/μL) or externally amplified
(PCR amplicon) DNA. All PCRs were performed in an
Eppendorf Mastercycler® ep (Westbury, NY, USA). Master-
mixes were adjusted accordingly for increases in total reac-
tion volume.
Cycling conditions for the primary reaction were as fol-
lows: denature at 94°C for 1-min, 1 cycle; denature at 94°C
for 45-sec, anneal at 55°C for 45-sec, extension time of 1.5-
min at 60°C, 40 cycles (35 cycles for secondary PCR); and
a final extension cycle of 60°C for 5-min. Products from
each primary and secondary PCR were individually visual-
ized by UV illumination after gel electrophoresis using a
1.5% concentration of Agarose, Genetic Technology Grade
(MP Biochemicals, LLC, Solon, OH, USA). Each allele
was characterized by family allele-type based upon visual-
ization of bands after amplification with family-specific
primers. A 100 bp DNA ladder (Invitrogen™, Carlsbad,
CA, USA) was used to determine product size.
Sequencing of Pfmsp1-19KD
Products from secondary PCRs performed in 100 μL total
reaction volume were individually visualized by UV illumi-
nation after gel electrophoresis using a 1.5% concentration
of UltraPure™ Agarose 1000 (Invitrogen™, Carlsbad, CA,
USA). PCR products were isolated and then purified using
a Gel Extraction Kit (Qiagen®, Valencia, CA, USA). Puri-
fied PCR products at a final concentration of 10 ng/μL were
sequenced. The 5' and 3' primers [2.0 μM] for each allelic
family were used to sequence their respective alleles. All
sequencing was performed on an ABI 3730 Genetic Ana-
lyzer (Applied Biosystems, Foster, CA, USA) by the Uni-
versity of Alabama at Birmingham, Howell and ElizabethSutton et al. Malaria Journal 2010, 9:3
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Heflin Center for Human Genetics. Sequences were prelim-
inarily viewed using Chromas 2.33 (©2003-2008 Technely-
sium Pty Ltd), but aligned using ClustalX2 [19].
PCR-genotyping of Pfmsp1-B2
Pfmsp1-B2 genotyping was attempted on all available sam-
ples that were microscopy and/or PCR positive for P. falci-
parum  between 2003 and 2007 (781 P. falciparum
infection-months). Given the active case detection study
design (with frequent sampling during follow-up) it was
possible that an individual could be sampled multiple times
over the course of weeks. Infections were defined as one or
more malaria-positive sample point(s) during the follow-
up. All sampled time points within one month before and
after the infection were considered. The sampling could
begin before the initial malaria positive sample or after,
with an overall sampling time frame of ≤30 days (four
weeks of sampling follow-up planned). For this reason,
infections are called "infection-months," and this is the
denominator used when considering the number of infec-
tions followed and the frequency of the different parasite
alleles detected [20]. The appendence of 2005-2007 geno-
typing data to previously reported years 2003-2004 [20]
allows for the establishment of a continued baseline of the
potential population-level diversity. Previously reported
genotyping methods were used for main allelic family anal-
ysis [20-23]. Additionally, all permutations of primers were
used to detect any allelic families that are the result of
recombination (Figure 1, A and 1C). PCR products for the
K1, Mad20, and RO33 allelic families were observed; no
Mad20-RO33 recombinant alleles were observed [20,21].
Measurement of IgG
ELISA for total IgG was performed as described previously
[24,25]. Plates (Nunc-Immuno™ Polystyrene Plates, A Part
of ThermoFisher Scientific, Rochester, NY, USA) were
coated with 50 μL/well of recombinant PfMSP1-19KD (E-
KNG, Q-KNG, E-TSR, or Q-TSR) at a concentration of
0.25 ng/μL. Recombinant E-KNG, E-TSR, and Q-KNG
PfMSP1-19KD antigens were obtained from the MR4 divi-
sion of ATCC (Manassas, VA). Recombinant Q-TSR was
provided by David Kaslow. The plates were then blocked
Figure 1 A-C - Genotyping methods for Pfmsp1-42KD and Pfmsp1-B2. A) Schema of Pfmsp1, indicating contrasting regions of conservation and 
variability. B) Highlights the Pfmsp1-42KD region of Pfmsp1. The polymorphic nature of Pfmsp1-33KD is indicated by the darker shades at the C-terminal 
end of the Mad20 allele (tan) and K1 allele (blue), while the lighter shades are used to indicate increased conservation. Colored arrows, defined in the 
figure, are used to illustrate the position of the primers used in PCR amplification. The colored arrows, with the same definition as found in (A), are used 
to illustrate the combination of primers (Mad20 or K1) used when testing for permutations that may have been observed due to interfamily sexual 
recombination. C) Highlights the three allelic families detected as a result of using the Roberts et al [22] method. Stemming from the polymorphic 
Pfmsp1B2 region, illustrated as the red block, are those three allelic families: Mad20 (tan), K1 (blue), RO33 (pink). Darker shades at the center of Mad20 
and K1 are used to indicate increased genetic variation due to it the presence of a variable repeat-length region. Colored arrows, defined in the figure, 
are used to illustrate the position of the primers used in PCR amplification. The colored arrows, with the same definition as found in (A), are used to 
illustrate the combination of primers (5' or 3') used when testing for permutations that may have been observed due to interfamily sexual recombi-
nation.
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with BBS and 1% Bovine Serum Albumin (BSA). Sera
samples were diluted 1:100 in Sera Dilution Buffer (1.5%
nonfat milk in AB washing solution [0.15 M Na2HPO4,
0.15 M NaH2PO4, NaCl, 0.05% Tween20, and 0.05%
BSA]) and added to plates coated with PfMSP1-19KD anti-
gens. After incubating the plates for two hours and then
washing them with AB Wash, 50 μL of secondary antibody
(horseradish peroxidase-conjugated goat-anti-human-IgG
(Chemicon, Millipore™ Billerica, MA, USA) was added to
each well at a concentration of 1:4000. After a second two-
hour incubation period, the plates were again washed with
AB Wash and 50 μL of 3,3', 5,5'-tetramethylbenzidine
(KPL, Inc., Gaithersburg, MD, USA) was added to each
well. The reaction was stopped after approximately six
minutes using 25 μL of 0.25 M HCl per well. The plates
were read at 450 nm (A450) with an ELISA plate-reader
(Bio-Rad, Heracles, CA, USA).
Six serum samples from healthy non-exposed Peruvians
were used as negative controls. The positive controls
included a "positive pool" made-up of 5 different P. falci-
parum-infected individuals. A negative cut-off value (the
average of the negative control samples plus two times the
standard deviation of the negative controls) was calculated
for each experiment day to determine the difference
between negative and positive optical density (OD) thresh-
olds for each antigen.
Statistical analysis of PfMSP1-19KD ELISA data
The statistical study of the antibody response data for the
PfMSP1-19KD allele-types was completed in two analyses.
The first compared paired, continuous OD values (N =
105), while the second compared the frequencies of cate-
gorical classifications (positive versus negative) of each
value. In both analyses, "positive" describes any result
greater than the negative cut-off value and "negative"
describes any value less than or equal to the negative cutoff
value. All statistical analyses were performed using Graph-
Pad Prism (version 4.00 for Windows, GraphPad Software,
San Diego, California, USA).
Antibody depletion ELISAs
To evaluate the cross-reactivity of antibodies against each
PfMSP1-19KD allele in sera samples from 18 different
individuals, an ELISA was performed after antibody deple-
tion with each of the allelic forms. This method was similar
to the immunoassays used by Mamillapalli et al [14], where
the assay was called "Antibody depletion ELISAs." After
diluting the patient sera at 1:100 in AB Wash + 1.5% milk,
the sera solution was placed in the first row of a 96-well pri-
mary plate (primary plates were coated with 50 ng of anti-
gen per well in the first row of the plate and 100 ng of
antigen per well in the seven consecutive rows). Patient
sera were plated separately on E-KNG, Q-KNG, E-TSR,
and Q-TSR primary plates. After incubating the sera for 30
min, it was then transferred to the next row of wells, where
it was again incubated for 30 min. The wells of the primary
plate were washed once with 50 μL of AB wash after each
transfer, and the residual wash buffer was then placed with
the sera to recover as much antibody as possible from the
primary plates. Seven such transfers were performed. After
the last transfer, the sera was transferred to secondary
ELISA plates--one secondary plate for each of the four
allele-types coated at 50 ng of antigen per well in all wells
(Figure 2)--where it was incubated for one hour, and then
the wells of both the primary and secondary plates were
washed 4 times with AB wash and the ELISA was com-
pleted as described above in "Measurement of IgG."
Results
Genetic diversity of PfMSP1-33KD and PfMSP1-19KD
From 781 P. falciparum infection-months with DNA avail-
able for testing, DNA samples were selected representing
187 infections (participants). Sample selection was guided
by gender, age, community, and year of infection (Table 1).
The genotyping results were clear for all 187 samples, but
reliable sequences were only achieved on 160 of the 187
samples.
There was no allelic variation observed within PfMSP1-
33KD, as all 160 participant samples were identified as the
Mad20 allele-type in this region. Primer permutations were
used in the secondary PCR to determine if recombinatory
events had occurred in recent evolutionary history between
family allele-types in this region. The semi-nested second-
ary PCR did not suggest recombination throughout
PfMSP1-33KD. When PfMSP1-19KD was sequenced, 159
(99.4%) samples were identified as the Q-KSNG-F variant,
while only one sample (0.6%) was identified as the E-
KSNG-L variant. The E-KSNG-L variant was detected in
year-2003 and not in the four subsequent years of this study
(Table 2).
Genetic diversity of Pfmsp1-block 2
There were 951 Pfmsp1-B2 alleles detected in the 781
infection-months in this study from 2003-2007. Of the 781
infection-months, 80.0% were single infections, while
20.0% were complex infections (defined by the detection of
more than one Pfmsp1-B2 allele in a single sample or
throughout the infection-month).
The K1, Mad20, and RO33 allelic families that have been
detected globally in prior studies were detected in Zungaro-
cocha. Three K1 allele-types (170 bp, 195 bp, 220 bp),
three Mad20 allele-types (200 bp, 210 bp, 230 bp), and one
RO33 allele-type (140 bp) were observed. Of the 951
alleles detected, 499 (52.5%) were K1, 431 (45.3%) were
Mad20, and 21 (2.2%) were RO33 (Table 3). Though the
K1 and Mad20 allelic families appear to be equally distrib-
uted, when these infections were analysed over time there
was a decrease in the detection of K1 allele-types (74.7% toSutton et al. Malaria Journal 2010, 9:3
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44.7% between 2003-2007), complemented by an increase
in the detection Mad20 allele-types (20.2% to 55.3%
between 2003-2007). The RO33 main allelic family was
observed at a low frequency throughout all years and as part
of a mixed infection in all instances but one. Individual
allele-types for Pfmsp1-B2 allelic families can be found in
Table 3.
Antibody responses to PfMSP1-19KD IgG
Total IgG antibody responses to all four PfMSP1-19KD
allele-types were tested on 105 samples. Of the 105 individ-
uals, 62 (59.1%) were positive for all alleles, and 27
(25.7%) were negative for all alleles. Considering the opti-
cal density (OD) readings, the mean values for Q-KNG and
Q-TSR were the highest of the four alleles, (1.139 and
0.983, respectively), followed by EKNG (mean = 0.963)
and ETSR (0.904) (Table 4).
However, a one-way analysis of variance (ANOVA,
Friedman test) comparing values for all four PfMSP1-
19KD allele-types indicated that there was a significant dif-
ference between variances (P < 0.0001; Friedman statistic =
58.25) when compared together. Table 5 shows the between
groups post-tests performed during this analysis, indicating
that there were significant differences between Q-KNG and
E-KNG, Q-KNG and Q-TSR, and Q-KNG versus E-TSR
(all P < 0.0001), while there were no significant differences
between any of the other allelic combinations.
Allele-specific/shared site responses
First, individuals' responses to each PfMSP1-19KD allele-
type were considered. Figure 3 shows positive (stratified
into high positive [HP], medium positive [MP], and low
positive [LP]) and negative categorical values for each
allele in a pair-wise manner. E-KNG responses matched Q-
KNG responses 85.7% of the time and E-TSR 77.1% of the
Figure 2 Experimental design for Antibody depletion ELISA. A representative sample is shown. Patients' sera were plated in duplicate and in 4 
replicates in the first row on each type of "primary" plate (E-KNG, Q-KNG, E-TSR, and Q-TSR). The sera were then transferred down the plate seven times, 
incubating for half an hour before each transfer. After incubating the patient sera in the last row of the primary plate, it was transferred to a secondary 
plate of each allele.
Sample 1
1° Plate:
Q- KNG, E-KNG,
Q-TSR, or E-TSR
Q-KNG Q-KNG Q-KNG Q-KNG
Q-KNG E-KNG Q-TSR E-TSR
From Q -KNG 1 Plate:
From E-KNG 1 Plate:
From Q-TSR 1 Plate:
From E- TSR 1 Plate:
2° Plate:
Q- KNG, E- KNG, 
Q-TSR, and E-TSRSutton et al. Malaria Journal 2010, 9:3
http://www.malariajournal.com/content/9/1/3
Page 7 of 13
time. However, the E-KNG responses matched Q-TSR
responses only 73.3% of the time. Similarly, Q-KNG
matched Q-TSR 77.1% and E-TSR 72.4% of the time. Q-
TSR and E-TSR were consistently close in value 83.8% of
the time.
In a paired correlation analysis comparing the continuous
OD measurements to the four allele-types, E-TSR and Q-
TSR were found to correlate at the highest rate (correlation
coefficient = 0.938, see Table 6), although E-KNG and Q-
KNG had a similarly high correlation coefficient (0.935).
The lowest correlation coefficient was found to be between
E-KNG and E-TSR, but it was still relatively high at 0.852.
Correlations between all pairings were significant (P <
0.0001).
Antibody depletion experiments
The next step consisted of a series of antibody depletion
experiments, to evaluate the site-shared (cross-reactive)
versus allele-specific responses to the four PfMSP1-19KD
allele-types. In essence, the antibodies to sites shared
between the antigens on the primary and secondary ELISA
plates are absorbed (depleted) on the primary plate, so that
only antibody to the differing antigen sites are left to bind to
the secondary plate.
Eighteen different serum samples were tested, 12 of
which had tested high positive when evaluated by ELISA
for PfMSP1-19KD IgG to each of the four different allele-
types, and the remaining six which tested low positive.
These individuals were all infected with the Q-KNG allele-
type parasite at some time between one and three months
before this sera sample was collected (Figure 2).
Table 1: Distribution of population variables used in sample selection for Pfmsp1-19KD genotyping
Variable N Distribution
Gender Male 80 0.50
Female 80 0.50
Age ≤14-years 60 0.38
≥15-years 100 0.63
Collection Year 2003 29 0.18
2004 48 0.30
2005 41 0.26
2006 42 0.26
Community Llanchama 25 0.16
Ninarumi 54 0.34
Puerto Almendra 36 0.23
Zungarococha 29 0.18
Other 16 0.10
Table 2: Pfmsp1-42KD PCR genotyping and sequencing results
Pfmsp1-
33KD
N Frequency Pfmsp1-19KD SNP and Position GenBank 
No.
1644 1691 1699 1700 1701 1716
Mad20 159 99.4% Q KSNGF FJ959104
Mad20 1 0.6% E KSNGL FJ959105Sutton et al. Malaria Journal 2010, 9:3
http://www.malariajournal.com/content/9/1/3
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Patient sera depleted with the Q-KNG allele-type did not
have a positive antibody response remaining to any of the
four allele-types, indicating that there was not a -TSR or E-
specific antibody response. With respect to the Q- or -KNG
specific responses, it was observed that there remained a
strong E-KNG response in eight of the 18 individuals after
depleting with Q-TSR, and, similarly, after depleting with
E-KNG 7 of the 18 individuals had a Q-TSR antibody
response. Considering all the allele-specific antibody deple-
tion permutations (as shown in Figure 4), after antibody
depletion with Q- and/or -TSR allelic forms, 14 individuals
had antibody responses. Of these 14 individuals, 11 had
both -KNG and Q- specific responses while all 14 had Q-
specific antibody responses (even in the absence of the -
KNG). Figure 4 shows the mean antibody level after each
of the antibody depletions.
Discussion
The genetic diversity of PfMSP1-19KD and the potential
allele-specific immunity versus shared site immunity must
be known for any population undergoing a vaccine trial.
Studies in regions of high transmission have suggested that
naturally occurring protective antibody responses against
the PfMSP1-19KD vaccine candidate might be allele-spe-
Table 3: Pfmsp1-B2 main allelic family allele-type frequencies
Main Family Allele-type (bp) Frequency (N = 951)
K1 170 12.1%
195 39.9%
220 0.5%
Mad20 200 4.9%
210 39.6%
230 0.7%
RO33 140 2.2%
Table 4: Descriptive Statistics for PfMSP1-19KD antigens
E-KNG Q-KNG Q-TSR E-TSR
Number of values 105 105 105 105
Minimum -0.435 0.051 0.029 -0.009
25% Percentile 0.308 0.465 0.200 0.164
Median 0.971 1.181 0.968 0.796
75% Percentile 1.585 1.772 1.695 1.625
Maximum 2.126 2.081 2.109 2.075
Mean 0.963 1.139 0.983 0.904
Std. Deviation 0.663 0.629 0.696 0.693
Std. Error 0.065 0.061 0.068 0.068
Lower 95% CI of mean 0.835 1.017 0.848 0.770
Upper 95% CI of mean 1.091 1.260 1.118 1.038
Coeff. of variation 68.84% 55.23% 70.84% 76.62%Sutton et al. Malaria Journal 2010, 9:3
http://www.malariajournal.com/content/9/1/3
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cific to one or more of the four main allelic forms: E-KNG,
E-TSR, Q-KNG, and Q-TSR. The global distribution and
evidence for differential recognition of these four major
allele-types provides further support for allele-specific
immunity and clinical protection [4,7-11,26-31]. Although
bearing hallmarks of allele-specific selection, the genetic
diversity within PfMSP1-19KD could be explained by
genetic drift. Moreover, there has only been one study that
investigated this allele-specific immunity in naturally
infected individuals. This well-designed study showed evi-
dence for allele-specific and shared site antibody responses,
but only three individuals were tested [14]. Additionally,
there might be allele-specific antibody responses only at the
time of acute infection, with no association to protective
immunity upon subsequent infection.
In Iquitos, Peru, after 40 years of effective malaria elimi-
nation campaigns, P. falciparum reemerged in 1994 and
continued as an epidemic until 1998 [15,16]. Since 1998,
there has been sustained low transmission of P. falciparum
(< 0.5 infections/person/year) [16]. It was demonstrated
that there is considerable genetic diversity in the polymor-
phic Pfmsp1-B2. Despite this potential for elevated diver-
sity in this region of low transmission, it did not predict an
increase in the population-level diversity within Pfmsp1-
19KD. However, no population-level diversity associated
with the Pfmsp1-42KD was found, as all 160 samples were
of the Mad20 allele-type. An insignificant amount of popu-
lation-level diversity in the Pfmsp1-19KD was found, with
the Q-KSNG-L variant comprising 99.4% of the total popu-
lation-level diversity and the E-KSNG-F variant compris-
ing 0.6% of the population-level diversity. Using samples
from this study site and three other study sites, Chenet et al
[32] reported finding only the Q-KSNG-L allelic form of
PfMSP1-19KD in all four study sites.
This extreme conservation is surprising. Even though low
genetic diversity in the C-terminal domain was expected,
there was enough diversity in the PfMSP1-B2 (all three
main families: K1, Mad20 and RO33) for us to expect
Table 5: One-way ANOVA: E-KNG vs Q-KNG vs Q-TSR vs E-
TSR
Dunn's Multiple 
Comparison Test
Summary
E-KNG vs Q-KNG ***
E-KNG vs Q-TSR ns
E-KNG vs E-TSR ns
Q-KNG vs Q-TSR ***
Q-KNG vs E-TSR ***
Q-TSR vs E-TSR ns
Figure 3 Tabular comparison of concordance between the four Pf 
MSP1-19KD alleles. N = 105, dark grey = high positive antibody re-
sponse (values greater than 2 * negative cut-off for each allele), medi-
um grey = medium positive response (values between 1.5 * the 
negative cut-off and 2 * the negative cut-off), light grey = low positive 
response (values between the negative cut-off and 1.5 * negative cut-
off), and white = negative antibody response (values less than the neg-
ative cut-off). Each row represents a different code/date.Sutton et al. Malaria Journal 2010, 9:3
http://www.malariajournal.com/content/9/1/3
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increased diversity in PfMSP1-19KD, consistent with what
may have entered during the epidemic between 1994 and
1998 and/or migrated in (geneflow) during the sustained
post-epidemic, low transmission years. This epidemic in the
Peruvian Amazon likely included parasites migrating from
Brazil and other South American countries [15,16]. How-
ever, even if one or more of the other Pfmsp1-19KD allele-
types were introduced into this population and not main-
tained due to an immune response selection, it is likely that
they would be lost due to genetic drift in low transmission.
The diversity in Pfmsp1-B2 and Pfmsp1-19KD in various
studies is shown in Additional File 1.
Table 6: Correlation analysis between the 4 PfMSP1-19KD alleles
E-KNG Q-KNG Q-TSR E-TSR
Correl. 
Coeff
P value Correl. 
Coeff
P value Correl. 
Coeff
P value Correl. 
Coeff
P value
EKNG -- 0.935 < 0.0001 0.878 < 0.0001 0.852 < 0.0001
QKNG 0.935 < 0.0001 - - 0.894 < 0.0001 0.868 < 0.0001
QTSR 0.878 < 0.0001 0.894 < 0.0001 - - 0.938 < 0.0001
ETSR 0.852 < 0.0001 0.868 < 0.0001 0.938 < 0.0001 - -
Figure 4 Immunodepletion results. The mean residual antibody OD values are shown on the y-axis, antigens that underwent immunodepletion 
are shown on the z-axis, and secondary antibody responses are shown on the x-axis. The range for all samples was 0.019-0.142. The standard error of 
most comparisons was low (with a range of 0.00-0.05), and so not shown on this graphic.Sutton et al. Malaria Journal 2010, 9:3
http://www.malariajournal.com/content/9/1/3
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Previous work has shown a strong association between
this population's antibody response to PfMSP1-19KD and
protection against febrile illness and parasite density [24]. It
has also been shown that anti-PfMSP1-19KD antibody
responses appear long-lasting (at least two months in most
individuals and longer than four months in many individu-
als) with more than 50% of the infections detected being
asymptomatic [24]. It is possible that these factors might
explain the lack of genetic diversity in the Pfmsp1-19KD,
but regardless if there was protection to allele-specific sites
within PfMSP1-19KD, some selection for PfMSP1-19KD
allelic diversity would have been anticipated. Of course, it
is possible that this protection (asymptomatic infections
associated with the antibody response) is not anti-PfMSP1-
19KD mediated - and so there would be no immunologic
selection on PfMSP1-19KD at all. It is also possible that the
antibody response is to shared sites/conserved antigenic
determinants and so any pre-existing alternate allele and/or
mutation to another allele-type has not been selected for
over time and, therefore, lost.
To evaluate whether there are allele-specific responses,
the IgG antibody responses to each of the alleles was inves-
tigated, and then a series of antibody depletion ELISAs
were performed. Although the highest average antibody
levels were shown by Q-KNG and Q-TSR, categorical
responses to E-KNG and Q-KNG were more similar to each
other than to Q-TSR or to E-TSR. In turn, responses to Q-
TSR and E-TSR were found to be more similar than to E-
KNG or Q-KNG. Earlier studies concluded that this sug-
gests less cross reactivity between the secondary epidermal
growth factor (EGF) domain of the 19KD region of
PfMSP1 (-KNG versus -TSR) [13]. However, to truly deter-
mine if there is a -KNG versus -TSR or E-K versus Q-K
allele-specific response, a more sophisticated antibody
depletion experiment is required.
Because Q-KNG is the only PfMSP1-19KD allele
detected in this region since 2004, all measured antibody
responses must be to shared sites or Q-KNG-specific.
Indeed, it was found that after immunodepletion with the
recombinant Q-KNG allele there was little response to any
of the four allelic-forms of PfMSP1-19KD. In addition, it
was observed that anti-Q-KNG antibodies in patient sera
were not depleted by either E-KNG or E-TSR, although Q-
TSR depleted Q-KNG antibodies in 10 of 18 individuals.
Therefore, the majority of the response appears to be to
conserved/shared antigenic sites, with some allele specific
response, particularly to the Q-. Although a parasite having
E-KNG was detected in year 2003, there was no allele-spe-
cific response detected to E- in these individuals.
Whether or not this "conserved" antibody response to
PfMSP1-19KD is protective is a subject which requires fur-
ther study. An ongoing study in this population has pro-
vided evidence that this response is associated with
protection against clinical illness and parasitaemia. For
example, children with a positive PfMSP1-19KD antibody
response one to two weeks prior to infection (i.e. the child
was previously infected with P. falciparum) were just as
likely to have an asymptomatic infection as an adult in this
population. Conversely, adults with a negative antibody
response 1-2 weeks prior to infection were just as likely to
have a symptomatic infection as a child in this population.
This and other findings agree with the many other studies
suggesting that antibodies to PfMSP1-19KD are associated
with protection [6,5,10,34-36]. A study of the same individ-
uals' successive infections over time is being performed to
thoroughly test if antibody responses to shared sites of
PfMSP1-19KD are associated with protection. This
involves testing how immune responses develop over time
to various malaria antigens and how one or more of the
antibody responses are associated with the development of
exposure-related immunity. Furthermore, this highly Q-
KNG exposed population will make it possible to take the
anti-PfMSP1-19KD antibody and determine if it will cause
growth inhibition of P. falciparum parasites during in vitro
culture.
Conclusions
A non-allele specific antibody response in PfMSP1-19KD
may explain why other allelic forms have not been main-
tained or evolved in this population. This has important
implications for the use of PfMSP1-19KD as a vaccine can-
didate. It is possible that Peruvians have increased antibody
responses to the shared sites of PfMSP1-19KD, either due
to exposure/parasite characteristics (like complexity of
infection, Branch et al [23]) or due to a human-genetic pre-
disposition. Alternatively, these allelic polymorphisms are
not immune-specific even in other geographic regions,
implying these polymorphisms may be less important in
immune evasion that previous studies suggest.
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